Amanda Downey, MD
This is a single site, single dose clinical trial of intravenous (IV) ketamine for medically hospitalized adolescents and young adults with anorexia nervosa or atypical anorexia nervosa. Eating disorder symptoms will be measured pre- and post-ketamine infusion. Investigators hypothesize that ketamine will increase cognitive flexibility, making medical hospitalizations less distressing by improving the ability to learn new, positive associations with food.
Inclusion Criteria: 1. Age 16-26 years old 2. Meets diagnosis of anorexia nervosa (AN) or atypical anorexia nervosa (atypical AN) per DSM-5 criteria on admission 3. Admitted to the medical hospital for malnutrition 4. No changes to psychiatric medications for month prior to trial enrollment 5. Agree to use a highly effective form of contraception for at least two weeks following ketamine administration 6. Have an outpatient primary care provider, medical provider, or behavioral health provider or psychiatrist who is actively managing or coordinating care Exclusion Criteria: 1. Lifetime hist…
Ketamine will be delivered intravenously at 0.5 mg/kg over 40 minutes.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.